- Home
- CUE vs ORMP Comparison
CUE vs ORMP Comparison
Compare CUE & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- ORMP
- Stock Information
- Founded
- CUE 2014
- ORMP 2002
- Country
- CUE United States
- ORMP United States
- Employees
- CUE 41
- ORMP N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- ORMP Biotechnology: Pharmaceutical Preparations
- Sector
- CUE Health Care
- ORMP Health Care
- Exchange
- CUE Nasdaq
- ORMP Nasdaq
- Market Cap
- CUE 52.8M
- ORMP N/A
- IPO Year
- CUE 2018
- ORMP N/A
- Fundamental
- Price
- CUE $0.79
- ORMP $2.13
- Analyst Decision
- CUE Strong Buy
- ORMP Hold
- Analyst Count
- CUE 3
- ORMP 1
- Target Price
- CUE $3.00
- ORMP N/A
- AVG Volume (30 Days)
- CUE 323.3K
- ORMP 63.2K
- Earning Date
- CUE 08-13-2025
- ORMP 08-15-2025
- Dividend Yield
- CUE N/A
- ORMP N/A
- EPS Growth
- CUE N/A
- ORMP N/A
- EPS
- CUE N/A
- ORMP N/A
- Revenue
- CUE $7,991,000.00
- ORMP $2,000,000.00
- Revenue This Year
- CUE N/A
- ORMP N/A
- Revenue Next Year
- CUE $23.84
- ORMP N/A
- P/E Ratio
- CUE N/A
- ORMP N/A
- Revenue Growth
- CUE 13.83
- ORMP 196.74
- 52 Week Low
- CUE $0.45
- ORMP $1.82
- 52 Week High
- CUE $1.99
- ORMP $3.09
- Technical
- Relative Strength Index (RSI)
- CUE 51.10
- ORMP 46.01
- Support Level
- CUE $0.65
- ORMP $2.10
- Resistance Level
- CUE $0.83
- ORMP $2.20
- Average True Range (ATR)
- CUE 0.07
- ORMP 0.07
- MACD
- CUE 0.01
- ORMP -0.00
- Stochastic Oscillator
- CUE 30.43
- ORMP 27.78
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.